title: [Ambulatory care of chronic headache secondary to abuse of ergot preparations].
abstract: OBJECTIVE
  To analyse the results of out-patient treatment with diminishing doses of oral dihydroergotamine for patients with chronic migraine resulting from ergotics abuse.
  
  
  METHODS
  A prospective and descriptive intervention study.
  
  
  METHODS
  County hospital. Neurology out-patient clinic.
  
  
  METHODS
  All the patients with chronic migraine as a side-effect of abuse of ergotic preparations who were referred to neurology out-patients over 18 months.
  
  
  METHODS
  1) Patients were told verbally of the causes of their migraine; 2) suppression of the ergotics, using diminishing doses of dihydroergotamine (Dihydergot gotas); 3) Prophylactic treatment with flunarizine (Sibelium); 4) Symptomatic treatment with sodic naproxen (Antalgin 550); 5) monthly and three-monthly check-up.
  
  
  RESULTS
  Over 18 months 25 patients with migraines due to ergotic abuse (6.7% of total migraines) were included. 4 were men; 21 women. Their average age was 43 (SD: 13). At one month the response was excellent in 19 patients (76%), good in 3 (12%) and bad in 3 (12%). At three months, the response was excellent in 17 patients (68%), good in 4 (16%), bad in 2 (8%) and 2 did not attend for the check-up (8%).
  
  
  CONCLUSIONS
  1) Out-patient treatment with diminishing doses of oral dihydroergotamine is effective in treating chronic migraine due to ergotics abuse. 2) The general practitioner should intervene in the identification and prevention of ergotics abuse.
authors.affiliation: Servicio de Neurología, Hospital Societat de Socors Mutus de Mollet, Barcelona.
authors.forename: A
authors.initials: A
authors.lastname: Cano
authors.forename: J
authors.initials: J
authors.lastname: Roquer
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002908:Chronic Disease; D004087:Dihydroergotamine / Q000008:administration & dosage / Q000627:therapeutic use; D004876:Ergot Alkaloids; D005260:Female; D005444:Flunarizine / Q000627:therapeutic use; D006261:Headache / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use; D011446:Prospective Studies; D019966:Substance-Related Disorders; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004876:Ergot Alkaloids; D014665:Vasodilator Agents; D004087:Dihydroergotamine; D009288:Naproxen; D005444:Flunarizine
vernacular_title: Tratamiento ambulatorio de la cefalea crónica secundaria al abuso de preparados ergóticos.